|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We highlight recent insights into the ability of different protease agonists to bias PAR-2 signaling and the newly emerging evidence for an interplay between PAR-2 and membrane-anchored serine proteases, which may co-conspire to promote tumor progression and metastasis.
|
30610085 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PAR2 has been associated with many aspects regarding tumor progression, such as the production of pro-tumoral cytokines.
|
30172372 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Finally, through the generation of thrombin, EV can activate PAR-1, which evidently contributes to cancer progression, linking the coagulation system to tumor progression.
|
29761522 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In preclinical models, tumor cell PAR-1 appeared to be involved in the regulation of lung tumor growth and metastasis; however the role of PAR-1 in the lung tumor microenvironment, which is emerging as a key compartment in driving cancer progression, remained to be explored.
|
28173772 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Doxycycline directly targets PAR1 to suppress tumor progression.
|
28187433 |
2017 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
TGF-β induced PAR-1 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone.
|
28670703 |
2017 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In several human cancers, PAR1 expression and activation correlates with tumor progression and metastatization.
|
27600331 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Role of PXR in Hepatic Cancer: Its Influences on Liver Detoxification Capacity and Cancer Progression.
|
27760163 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The pregnane X receptor (PXR) is a transcription factor regulating genes involved not only in pharmacokinetics but also in chemotherapy resistance and cancer progression.
|
26141049 |
2015 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Proteinase-activated receptors (PARs) are a subfamily of G protein-coupled receptors (GPCRs) with four members, PAR1, PAR2, PAR3 and PAR4, playing critical functions in hemostasis, thrombosis, embryonic development, wound healing, inflammation and cancer progression.
|
24215724 |
2013 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Thus, loss of TERE1 during tumor progression reduces K-2 levels resulting in reduced transcription of SXR target genes.
|
23919967 |
2013 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TF signaling involving PAR2 and integrins has multiple effects on angiogenesis and tumor progression.
|
20434002 |
2010 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Recent work has elucidated mechanisms explaining correlations between cancer progression and the expression of GPCRs, such as a protease-activated receptor (PAR1), and G-proteins, such as Galpha(12/13).
|
17188489 |
2007 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Hypoxia or the counteradhesive matricellular protein SPARC/BM-40 (SPARC: secreted protein acidic rich in cysteine) overexpressed during cancer progression also commutated PAR-1 to cellular invasion through the cGMP/protein kinase G (PKG) cascade, RhoA inactivation, and Rac1-dependent or -independent signaling.
|
16091733 |
2005 |